NCT04941599View on ClinicalTrials.gov

2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)

PHASE2RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

February 14, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Familial Hypercholesterolemia
Interventions
DRUG

2-Hydroxybenzylamine

2-Hydroxybenzylamine (2-HOBA) 250 mg three tabs TID (po) for 6 weeks.

OTHER

Placebo

Placebo 250 mg three tabs TID (po) for 6 weeks.

Trial Locations (1)

37212

RECRUITING

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Vanderbilt University Medical Center

OTHER